Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Atheroma and antithrombotic agents].

I Juhan-Vague1

  • 1Laboratoire d'hématologie, CHU Timone, Marseille.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels.

Journal of thrombosis and haemostasis : JTH·2010
Same author

Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study.

International journal of obesity (2005)·2009
Same author

Systematically missing confounders in individual participant data meta-analysis of observational cohort studies.

Statistics in medicine·2009
Same author

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.

Journal of thrombosis and haemostasis : JTH·2008
Same author

Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study.

Journal of molecular medicine (Berlin, Germany)·2008
Same author

Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung.

Journal of thrombosis and haemostasis : JTH·2007
Same journal

Radiokymographic study of the kinetics of the middle arc and the hils in the normal subject.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

A medication for angina pectoris and pre-fibrillatory conditions; 1262 F; six years of clinical experience; action mechanism.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Circulatory changes following the injection of hypertonic saline solutions; application to the study of angina pectoris.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Alterations in coronary circulation during aortic insufficiency in young subjects.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Cardio-esophageal auscultation.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Hypertensive accidents following the injection of acetylcholine.

Archives des maladies du coeur et des vaisseaux·2010
See all related articles

Clotting factors and platelets contribute to atherothrombosis and lesion progression. Therapies targeting these factors show promise in preventing occlusive events and vessel wall damage.

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Pharmacology

Context:

  • Atherothrombosis involves clotting factors and platelets in thrombus formation and lesion progression.
  • Platelets release growth factors, stimulating smooth muscle cell proliferation.
  • Therapeutic trials have explored platelet-inhibiting drugs for occlusive events.

Purpose:

  • To review the role of clotting factors and platelet activity in atherothrombosis.
  • To assess the efficacy of antiplatelet agents and anticoagulants in preventing vascular lesions.
  • To highlight emerging therapeutic strategies targeting coagulation and fibrinolysis.

Summary:

  • Clotting factors and activated platelets are implicated in atherothrombosis, thrombus formation, and vascular lesion development.

Related Experiment Videos

  • Platelet anti-aggregants have shown efficacy in preventing occlusive events, but their role in preventing vessel wall lesions is less clear.
  • Elevated plasma levels of fibrinogen, factor VII, and plasminogen activator inhibitor-1 (PAI-1) are coronary risk markers.
  • Ongoing trials investigate vitamin K antagonists and metformin for their preventive effects on atherothrombosis.
  • Some antiplatelet and lipid-lowering drugs may reduce levels of fibrinogen, factor VII, and PAI-1.

    • Impact:

    • Understanding the multifaceted role of hemostatic factors in atherothrombosis is crucial for developing targeted therapies.
    • Identifying effective treatments for preventing both occlusive events and the progression of vascular lesions can improve patient outcomes.
    • The results of ongoing therapeutic trials are anticipated to guide future clinical practice in managing cardiovascular risk.